Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00227

Submission Number:
00227
Commenter:
Mark Hobbs
State:
Florida
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
The pharmacy marketplace is dominated by a few pharmacy benefit managers who practice without transparency or oversight and are driving the cost of drugs up for consumers. They do not allow pharmacists to save consumers money using contractual gag clauses. They practice predatory pricing by changes in prices that result in underpayments that put small businesses on the edge of bankruptcy. The FTC needs to intervene on the proposed merger of one of the largest PBMs with one of the largest insurers. It is not in the best interest of consumers and will lead to even higher drug costs in the future.